title: [Ischemic disease of the kidneys in a patient with morbid obesity: characteristics of the course and diagnostic policy].
authors.forename: V V
authors.initials: VV
authors.lastname: Fomin
authors.forename: V V
authors.initials: VV
authors.lastname: Safonov
authors.forename: N L
authors.initials: NL
authors.lastname: Kozlovskaia
authors.forename: S V
authors.initials: SV
authors.lastname: Moiseev
authors.forename: V I
authors.initials: VI
authors.lastname: Osipenko
authors.forename: O I
authors.initials: OI
authors.lastname: Tironishvili
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006291:Health Policy; D006801:Humans; D007511:Ischemia / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology*; D007674:Kidney Diseases / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use; D009765:Obesity / Q000150:complications*
chemical_list: D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D008790:Metoprolol; D009543:Nifedipine